Sponsor or institution

Clinical trials and research at Janssen Research & Development, LLC

• 73Clinical trials
• 1New in 30 days
• 45Countries

Newest trials

All recruiting trials (73)

• JNJ-101556143 plus Best Supportive Care for metastatic prostate cancer

  This study tests whether adding JNJ-101556143 to standard supportive care helps people with metastatic, hormone-resistant prostate cancer live longer than those who receive placebo plus supportive care.

  Recruiting at 4 sites Phase 3 Janssen Research & Development, LLC · El Paso, Texas and 3 other locations · NCT07906717

• Testing JNJ-101556143 in men with advanced prostate cancer that no longer responds to hormone therapy

  This study tests JNJ-101556143 in men with metastatic, hormone-resistant prostate cancer to see if tumors shrink or disappear.

  Recruiting at 14 sites Phase 2 Janssen Research & Development, LLC · Largo, Florida and 13 other locations · NCT07832292

• Long-Term Guselkumab Use in Adults with Inflammatory Bowel Disease

  This study looks at how long adults with Crohn's disease or ulcerative colitis stay on guselkumab in real-world care.

  Recruiting Janssen Research & Development, LLC · Amiens · NCT07822529

• New treatment option for advanced prostate cancer using JNJ-98768111

  A first-in-human study tests JNJ-98768111 to see how safe it is and find the best dose for people with advanced prostate cancer who have already tried other therapies.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 5 other locations · NCT07746713

• Test of JNJ-95597528 vs placebo in adults with moderate to severe asthma

  This trial checks whether JNJ-95597528 helps adults with moderate to severe asthma when added to their current treatment, compared with a placebo.

  Recruiting at 19 sites Phase 2 Janssen Research & Development, LLC · Westminster, California and 18 other locations · NCT07746687

• Esketamine nasal spray vs placebo for adults with treatment-resistant depression

  In adults who have not responded to at least two antidepressants, one of two doses of esketamine nasal spray is tested against placebo to see if it can help reduce depressive symptoms.

  Recruiting at 39 sites Phase 3 Janssen Research & Development, LLC · Redlands, California and 38 other locations · NCT07716098

• Nipocalimab in breast milk after a single IV dose in healthy lactating women

  This study tests how much nipocalimab shows up in breast milk after a single IV dose in healthy breastfeeding women.

  Recruiting Phase 1 Janssen Research & Development, LLC · Salt Lake City, Utah · NCT07669077

• Ramantamig plus Daratumumab vs standard regimens in newly diagnosed multiple myeloma without planned stem cell transplant

  This study tests whether ramantamig-D plus Daratumumab works better than DVRd or DRd in newly diagnosed myeloma patients who won’t have a stem cell transplant.

  Recruiting at 103 sites Phase 3 Janssen Research & Development, LLC · Darlinghurst and 102 other locations · NCT07665450

• Guselkumab in Breast Milk for Lactating Women on Guselkumab

  This study tests how much guselkumab is present in the breast milk of lactating women who are already receiving guselkumab for their approved conditions.

  Recruiting Phase 4 Janssen Research & Development, LLC · Chapel Hill, North Carolina · NCT07654751

• Aticaprant as add-on in schizophrenia: safety, tolerability, and how feasible it is to enroll

  This study tests whether adding aticaprant to an existing antipsychotic is safe and tolerable for people with schizophrenia, compared with placebo.

  Recruiting at 7 sites Phase 1 Janssen Research & Development, LLC · Garden Grove, California and 7 other locations · NCT07615426

• Ibrutinib and Venetoclax for Chronic Lymphocytic Leukemia in Real-World Care

  This study tests whether a fixed-duration Ibrutinib plus Venetoclax treatment works in real-world care for people with CLL or SLL.

  Recruiting Janssen Research & Development, LLC · Bucharest · NCT07602088

• Preventing Cytokine Release Syndrome with a single dose of tocilizumab before ramantamig in multiple myeloma

  A single pre-treatment dose of tocilizumab is being tested to see if it can prevent or lessen cytokine release syndrome in people with relapsed or refractory multiple myeloma who are treated with ramantamig.

  Recruiting at 60 sites Phase 2 Janssen Research & Development, LLC · Goodyear, Arizona and 59 other locations · NCT07589634

• Amivantamab with Lazertinib or Chemotherapy before surgery in EGFR-mutated NSCLC

  This study tests whether giving amivantamab together with lazertinib or with carboplatin and pemetrexed before surgery can slow or stop tumor growth in people with resectable EGFR-mutated NSCLC.

  Recruiting at 27 sites Phase 2 Janssen Research & Development, LLC · Duarte, California and 26 other locations · NCT07586202

• Persistence on Guselkumab in Romanian adults with moderate-to-severe plaque psoriasis

  This study looks at how many adults with moderate-to-severe plaque psoriasis continue guselkumab treatment over two years in Romania.

  Recruiting at 20 sites Janssen Research & Development, LLC · Bârlad and 19 other locations · NCT07582783

• Test of JNJ-78934804 vs guselkumab in moderately to severely active ulcerative colitis

  This study tests JNJ-78934804 against guselkumab to see which helps people with moderately to severely active ulcerative colitis feel better and stay safe over 48 weeks.

  Recruiting at 318 sites Phase 3 Janssen Research & Development, LLC · Scottsdale, Arizona and 317 other locations · NCT07577856

• JNJ-78934804 in Crohn’s disease: a comparison to guselkumab for moderate to severe cases

  This trial tests whether JNJ-78934804 works as well as guselkumab for adults with moderately to severely active Crohn’s disease over 48 weeks.

  Recruiting at 285 sites Phase 3 Janssen Research & Development, LLC · Scottsdale, Arizona and 286 other locations · NCT07577843

• Seltorexant (JNJ-42847922) as monotherapy for adults and older adults with major depressive disorder

  This trial will test whether seltorexant works better than a placebo to reduce depressive symptoms in adults and elderly people with major depressive disorder.

  Recruiting at 53 sites Phase 3 Janssen Research & Development, LLC · Bryant, Arkansas and 52 other locations · NCT07573176

• JNJ-95804306 in relapsed or refractory blood cancers

  This study tests JNJ-95804306 in people with relapsed or refractory hematologic cancers to find a safe dose and see if it helps control the disease when given alone or with standard therapy.

  Recruiting at 19 sites Phase 1 Janssen Research & Development, LLC · Indianapolis, Indiana and 18 other locations · NCT07572006

• Guselkumab in Ulcerative Colitis and Crohn’s Disease in Saudi Arabia: Real-World Use

  This study looks at how long people with moderate-to-severe Crohn’s disease or ulcerative colitis continue taking guselkumab in everyday clinical practice in Saudi Arabia.

  Recruiting Janssen Research & Development, LLC · Jeddah · NCT07541261

• HLD-0117 treatment for ER-positive metastatic breast cancer

  This will test whether the oral drug HLD-0117 is safe and can shrink tumors in people with ER-positive metastatic or locally advanced breast cancer who have progressed after prior treatments.

  Recruiting at 7 sites Phase 1 Janssen Research & Development, LLC · New Haven, Connecticut and 6 other locations · NCT07524855

• A comparison of JNJ-79635322 and teclistamab in relapsed or refractory multiple myeloma

  This study tests whether JNJ-79635322 works differently from teclistamab in people with relapsed or refractory multiple myeloma who have had prior therapy.

  Recruiting at 173 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 172 other locations · NCT07518186

• Guselkumab versus risankizumab for moderate-to-severe Crohn's disease

  This comparison tests whether guselkumab or risankizumab works better to reduce intestinal inflammation in people with moderately to severely active Crohn's disease.

  Recruiting at 162 sites Phase 3 Janssen Research & Development, LLC · Dothan, Alabama and 163 other locations · NCT07499232

• Nipocalimab for adults with moderate to severe systemic lupus erythematosus

  This trial tests nipocalimab versus placebo in adults with moderate to severe lupus to see if it reduces disease activity and symptoms.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Beverly Hills, California and 271 other locations · NCT07438496

• Pasritamig plus JNJ-86974680 for advanced prostate cancer

  This trial will test whether combining pasritamig with JNJ-86974680 is safe and to find the best dose for people with metastatic castration-resistant prostate cancer.

  Recruiting at 5 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 4 other locations · NCT07319871

• Real-world outcomes of TAR-200 for people with non-muscle invasive bladder cancer in the United States

  This project will see if TAR-200 helps people with non-muscle invasive bladder cancer stay disease-free longer after their first insertion during routine care in the U.S.

  Recruiting at 23 sites Janssen Research & Development, LLC · Birmingham, Alabama and 22 other locations · NCT07309445

• JNJ-95566692 alone or with JNJ-87801493 for relapsed or refractory B‑cell non‑Hodgkin lymphoma

  This trial tests whether the drug JNJ-95566692, given alone or with JNJ-87801493, helps people with relapsed or refractory B‑cell non‑Hodgkin lymphoma who have had prior therapies.

  Recruiting at 19 sites Phase 1 Janssen Research & Development, LLC · Clayton and 18 other locations · NCT07308132

• Amivantamab added to pembrolizumab and platinum chemotherapy versus pembrolizumab with platinum/5‑FU for recurrent/metastatic head and neck squamous cell carcinoma

  This trial will see if adding amivantamab to pembrolizumab and platinum‑based chemotherapy helps adults with recurrent or metastatic head and neck squamous cell carcinoma who have not yet had systemic treatment in the metastatic setting.

  Recruiting at 205 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 204 other locations · NCT07276399

• JNJ-79635322 versus a BCMA×CD3 bispecific antibody for relapsed or refractory multiple myeloma

  This trial tests whether JNJ-79635322 works better than a BCMA×CD3 bispecific antibody in people with relapsed or refractory multiple myeloma who have had at least three prior therapies.

  Recruiting at 157 sites Phase 3 Janssen Research & Development, LLC · Phoenix, Arizona and 156 other locations · NCT07258511

• Clinical outcomes of amivantamab-based treatment for advanced EGFR-mutated non-small cell lung cancer in everyday care.

  This project will see how amivantamab-containing treatments work for people with advanced non-small cell lung cancer who have common EGFR mutations.

  Recruiting at 90 sites Janssen Research & Development, LLC · Graz and 89 other locations · NCT07230691

• Esketamine plus standard care for adolescents with major depressive disorder and acute suicidal thoughts or behavior

  This will test whether adding intranasal esketamine to usual care helps hospitalized adolescents with major depressive disorder and acute suicidal thoughts or behavior feel better faster than a psychoactive placebo plus usual care.

  Recruiting at 49 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 48 other locations · NCT07227454

• Amivantamab plus olomorasib for metastatic KRAS G12C non-small cell lung cancer

  This trial tests whether combining amivantamab and olomorasib can slow tumor growth in people with metastatic non-small cell lung cancer that has a KRAS G12C mutation after platinum chemotherapy and PD‑L1 immunotherapy.

  Recruiting at 12 sites Phase 1/2 Janssen Research & Development, LLC · New York, New York and 11 other locations · NCT07227025

• Pasritamig plus docetaxel versus docetaxel for metastatic castration‑resistant prostate cancer

  This trial tests whether adding pasritamig to standard docetaxel chemotherapy helps men with metastatic castration-resistant prostate cancer stay progression-free on scans longer than docetaxel alone.

  Recruiting at 165 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 164 other locations · NCT07225946

• JNJ-89862175 treatment for advanced solid tumors

  This study will test JNJ-89862175 to find safe doses and see how it works in people with advanced solid tumors such as lung adenocarcinoma, certain renal cell cancers, and endometrioid ovarian and uterine cancers.

  Recruiting at 7 sites Phase 1 Janssen Research & Development, LLC · Orlando, Florida and 6 other locations · NCT07223125

• Guselkumab for people with psoriatic arthritis in routine care

  This study will test whether guselkumab given in routine clinical care reduces joint inflammation in people with psoriatic arthritis using musculoskeletal ultrasound to track changes.

  Recruiting at 20 sites Janssen Research & Development, LLC · Bari and 20 other locations · NCT07220824

• Nipocalimab versus efgartigimod for generalized myasthenia gravis

  This trial will test whether nipocalimab or efgartigimod works better to reduce muscle weakness in adults with AChR-positive generalized myasthenia gravis who have meaningful symptoms despite stable therapy.

  Recruiting at 30 sites Phase 3 Janssen Research & Development, LLC · Fullerton, California and 30 other locations · NCT07217587

• Icotrokinra for moderately to severely active Crohn's disease

  This trial will test whether icotrokinra helps people with moderately to severely active Crohn's disease reduce intestinal inflammation and symptoms compared with a placebo.

  Recruiting at 382 sites Phase 2/3 Janssen Research & Development, LLC · Chandler, Arizona and 394 other locations · NCT07196722

• Global registry for hemolytic disease of the fetus and newborn (HDFN)

  This project will follow pregnant people at risk for HDFN to see how often their fetuses or newborns develop anemia while receiving standard care.

  Recruiting at 16 sites Janssen Research & Development, LLC · Indianapolis, Indiana and 16 other locations · NCT07194070

• Pasritamig versus placebo for late-line metastatic castration-resistant prostate cancer

  This will test whether pasritamig plus best supportive care helps people with late-line metastatic castration-resistant prostate cancer live longer than placebo plus supportive care.

  Recruiting at 171 sites Phase 3 Janssen Research & Development, LLC · La Jolla, California and 175 other locations · NCT07164443

• Cilta‑cel with a fludarabine‑free or alternative lymphodepletion plan for multiple myeloma

  This trial tests whether giving cilta‑cel with a fludarabine‑free lymphodepletion or with an alternative timing after cyclophosphamide and fludarabine works and is safe for people with newly diagnosed multiple myeloma who are not candidates for high‑dose transplant.

  Recruiting at 16 sites Phase 2 Janssen Research & Development, LLC · San Francisco, California and 19 other locations · NCT07149857

• JNJ-95437446 for advanced-stage solid tumors

  This tests JNJ-95437446 to find a safe dose and check tolerability in people with advanced solid tumors, including colorectal cancer.

  Recruiting at 10 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 9 other locations · NCT07107230

• Combination treatment with JNJ-78278343 and JNJ-95298177 for prostate cancer

  This trial tests whether giving two experimental drugs together, JNJ-78278343 and JNJ-95298177, is safe and tolerable for men with metastatic castration-resistant prostate cancer.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 5 other locations · NCT07082920

• TAR-210 versus intravesical chemotherapy for high-risk non-muscle-invasive bladder cancer

  This trial will test whether TAR-210 prevents cancer recurrence better than standard bladder instillation chemotherapy (mitomycin C or gemcitabine) in people with high-risk non-muscle-invasive bladder cancer who have FGFR mutations or fusions.

  Recruiting at 111 sites Phase 3 Janssen Research & Development, LLC · Sun City, Arizona and 114 other locations · NCT06919965

• Bleximenib added to venetoclax and azacitidine for newly diagnosed NPM1- or KMT2A-mutated AML

  This trial will test whether adding bleximenib to venetoclax plus azacitidine helps people with newly diagnosed AML that has NPM1 or KMT2A mutations who cannot have intensive chemotherapy.

  Recruiting at 270 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 269 other locations · NCT06852222

• Testing HLD-0915 for advanced prostate cancer

  This study is testing a new oral medication called HLD-0915 to see if it can help men with advanced prostate cancer that hasn't responded to other treatments.

  Recruiting at 18 sites Phase 1/2 Janssen Research & Development, LLC · Colorado Springs, Colorado and 17 other locations · NCT06800313

• Combining JNJ-79635322 with Daratumumab or Pomalidomide for Multiple Myeloma Treatment

  This study is testing a new drug called JNJ-79635322 combined with either daratumumab or pomalidomide to see how safe and effective it is for people with multiple myeloma.

  Recruiting at 16 sites Phase 1 Janssen Research & Development, LLC · Denver, Colorado and 15 other locations · NCT06768489

• Comparing Amivantamab with FOLFIRI to Cetuximab/Bevacizumab with FOLFIRI for Colorectal Cancer

  This study is testing if a new treatment combining amivantamab with FOLFIRI can help people with certain types of colorectal cancer live longer and feel better compared to the standard treatment with cetuximab or bevacizumab plus FOLFIRI.

  Recruiting at 235 sites Phase 3 Janssen Research & Development, LLC · Chandler, Arizona and 250 other locations · NCT06750094

• Combining Amivantamab with Lazertinib or Chemotherapy for Advanced Lung Cancer

  This study tests if a new combination of amivantamab with lazertinib or chemotherapy can help people with advanced lung cancer that has certain genetic changes.

  Recruiting at 68 sites Phase 2 Janssen Research & Development, LLC · Daphne, Alabama and 204 other locations · NCT06667076

• Long-term evaluation of guselkumab for children with inflammatory bowel disease and juvenile arthritis

  This study tests how safe and effective the medication guselkumab is for children with inflammatory bowel disease or juvenile arthritis over a long period of time.

  Recruiting at 53 sites Phase 3 Janssen Research & Development, LLC · Atlanta, Georgia and 52 other locations · NCT06663332

• Testing JNJ-89402638 for advanced colorectal cancer

  This study is testing a new drug called JNJ-89402638 to see if it is safe and what the right dose is for people with advanced colorectal cancer that hasn't responded to other treatments.

  Recruiting at 12 sites Phase 1 Janssen Research & Development, LLC · Tucson, Arizona and 11 other locations · NCT06663319

• Comparing two treatments for advanced left-sided colorectal cancer

  This study is testing whether a new drug called amivantamab combined with standard chemotherapy works better than cetuximab with the same chemotherapy for people with advanced left-sided colorectal cancer that can't be surgically removed.

  Recruiting at 233 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 238 other locations · NCT06662786

• Long-term safety assessment of JNJ-81201887 for eye condition related to aging

  This study is testing the long-term safety of a new eye treatment for age-related vision loss in people who have already tried it before.

  Recruiting at 85 sites Phase 2/3 Janssen Research & Development, LLC · Tucson, Arizona and 103 other locations · NCT06635148

• Testing seltorexant for treating major depression with insomnia symptoms

  This study is testing if adding a new medication called seltorexant can help adults and older people with major depression and insomnia feel better when their current antidepressants aren't enough.

  Recruiting at 67 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 204 other locations · NCT06559306

• Evaluating nipocalimab and IVIG for preventing fetal and neonatal thrombocytopenia

  This study is testing if a new treatment called nipocalimab can help pregnant women with a history of fetal and neonatal thrombocytopenia keep their babies' platelet levels safe compared to standard treatment with IVIG.

  Recruiting at 37 sites Phase 3 Janssen Research & Development, LLC · Birmingham, Alabama and 37 other locations · NCT06533098

• Evaluating treatments to prevent taste changes from talquetamab in multiple myeloma patients

  This study is testing different treatments to see if they can help multiple myeloma patients avoid or lessen taste changes caused by the drug talquetamab.

  Recruiting at 37 sites Phase 2 Janssen Research & Development, LLC · San Francisco, California and 37 other locations · NCT06500884

• Evaluating nipocalimab for preventing fetal and neonatal alloimmune thrombocytopenia

  This study is testing whether nipocalimab can help pregnant women with a history of a blood condition called fetal and neonatal alloimmune thrombocytopenia prevent serious problems for their babies.

  Recruiting at 6 sites Phase 3 Janssen Research & Development, LLC · Leuven and 20 other locations · NCT06449651

• Testing amivantamab for recurrent or metastatic head and neck cancer

  This study is testing if a new drug called amivantamab, alone or with other treatments, can help people with recurrent or metastatic head and neck cancer feel better.

  Recruiting at 51 sites Phase 1/2 Janssen Research & Development, LLC · La Jolla, California and 55 other locations · NCT06385080

• Comparing TAR-210 to standard chemotherapy for bladder cancer treatment

  This study is testing if a new treatment called TAR-210 can help people with intermediate-risk bladder cancer live longer without their cancer coming back compared to standard chemotherapy options.

  Recruiting at 70 sites Phase 3 Janssen Research & Development, LLC · Little Rock, Arkansas and 192 other locations · NCT06319820

• Testing JNJ-87890387 for advanced solid tumors

  This study is testing a new drug called JNJ-87890387 to see how safe it is and what the right dose is for people with advanced solid tumors like kidney cancer, ovarian cancer, and lung cancer.

  Recruiting at 6 sites Phase 1 Janssen Research & Development, LLC · Grand Rapids, Michigan and 5 other locations · NCT06178614

• Treatment of CALR-Mutated Myeloproliferative Neoplasms with JNJ-88549968

  This study is testing a new treatment called JNJ-88549968 to see if it is safe and effective for people with CALR-mutated myeloproliferative neoplasms.

  Recruiting at 45 sites Phase 1 Janssen Research & Development, LLC · Goodyear, Arizona and 45 other locations · NCT06150157

• Combination treatment for advanced prostate cancer

  This study is testing a combination of two new drugs to see if they are safe and how well they work for people with advanced prostate cancer that hasn't responded to other treatments.

  Recruiting at 22 sites Phase 1 Janssen Research & Development, LLC · Aurora, Colorado and 21 other locations · NCT06095089

• Evaluating Guselkumab for Children with Active Crohn's Disease

  This study is testing if a new medication called guselkumab can help children with active Crohn's Disease feel better and improve their symptoms over a year.

  Recruiting at 85 sites Phase 3 Janssen Research & Development, LLC · Los Angeles, California and 84 other locations · NCT05923073

• Nipocalimab treatment for pregnant women at risk of severe fetal anemia

  This study is testing if nipocalimab can help pregnant women at risk of having babies with severe anemia due to a past condition, to see if it improves the health of their newborns.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · La Jolla, California and 68 other locations · NCT05912517

• Combining JNJ-78278343 with other treatments for advanced prostate cancer

  This study is testing a new treatment called JNJ-78278343 combined with other therapies to see if it helps people with advanced prostate cancer feel better and stay safe.

  Recruiting at 15 sites Phase 1 Janssen Research & Development, LLC · Sarasota, Florida and 14 other locations · NCT05818683

• Testing JNJ-79635322 for patients with advanced multiple myeloma or AL amyloidosis

  This study is testing a new drug called JNJ-79635322 to see how much of it is safe to give to people with advanced multiple myeloma or AL amyloidosis who haven't responded to other treatments.

  Recruiting at 25 sites Phase 1 Janssen Research & Development, LLC · Duarte, California and 28 other locations · NCT05652335

• Combining teclistamab and talquetamab with daratumumab and lenalidomide for newly diagnosed multiple myeloma

  This study is testing two new treatment combinations for people with newly diagnosed multiple myeloma to see if they work better than the standard treatment.

  Recruiting at 66 sites Phase 3 Janssen Research & Development, LLC · Gilbert, Arizona and 269 other locations · NCT05552222

• Evaluating amivantamab for advanced non-small cell lung cancer

  This study is testing if a new treatment combining amivantamab and another drug can help people with advanced non-small cell lung cancer, especially those with certain genetic mutations.

  Recruiting at 82 sites Phase 2 Janssen Research & Development, LLC · La Jolla, California and 109 other locations · NCT05498428

• Amivantamab treatment for advanced colorectal cancer

  This study is testing if a new drug called amivantamab, alone or with regular chemotherapy, can help people with advanced colorectal cancer.

  Recruiting at 44 sites Phase 1/2 Janssen Research & Development, LLC · Birmingham, Alabama and 52 other locations · NCT05379595

• Evaluating nipocalimab for adults with chronic inflammatory demyelinating polyneuropathy

  This study is testing a new treatment called nipocalimab to see if it can help adults with chronic inflammatory demyelinating polyneuropathy avoid relapses and feel better.

  Recruiting at 6 sites Phase 2/3 Janssen Research & Development, LLC · Centennial, Colorado and 119 other locations · NCT05327114

• Nipocalimab treatment for children with generalized myasthenia gravis

  This study is testing a new treatment called nipocalimab to see if it can help children with generalized myasthenia gravis who haven't responded well to other therapies.

  Recruiting at 15 sites Phase 2/3 Janssen Research & Development, LLC · Phoenix, Arizona and 18 other locations · NCT05265273

• Long-term follow-up for patients treated with cilta-cel

  This study is tracking the long-term effects and safety of a treatment called cilta-cel in people with multiple myeloma to see how they do over up to 15 years after their therapy.

  Recruiting at 37 sites Phase 4 Janssen Research & Development, LLC · Phoenix, Arizona and 49 other locations · NCT05201781

• Evaluating Nipocalimab for Adults with Generalized Myasthenia Gravis

  This study is testing a new drug called nipocalimab to see if it can help adults with generalized myasthenia gravis feel stronger and improve their daily activities compared to a placebo.

  Recruiting at 68 sites Phase 3 Janssen Research & Development, LLC · Paradise Valley, Arizona and 111 other locations · NCT04951622

• Testing bleximenib for treating acute leukemia

  This study is testing a new drug called bleximenib to see if it can safely help teenagers and adults with tough cases of acute leukemia.

  Recruiting at 85 sites Phase 1/2 Janssen Research & Development, LLC · Duarte, California and 101 other locations · NCT04811560

• Evaluating talquetamab for patients with relapsed or refractory multiple myeloma

  This study is testing a new drug called talquetamab to see if it can help people with relapsed or refractory multiple myeloma feel better and manage their disease.

  Recruiting at 14 sites Phase 2 Janssen Research & Development, LLC · Birmingham, Alabama and 77 other locations · NCT04634552

Quick answers

How many clinical trials run by Janssen Research & Development, LLC are recruiting right now?

73, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 45 countries. The most sites are in United States (64 trials), Spain (49 trials), France (38 trials), United Kingdom (35 trials), Italy (34 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 28, Phase 1: 17, Phase 2: 9, Phase 1/2: 5. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →